{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"126","value":"578"}]}],"title":"ANC +/- SEM at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"384","value":"1137"}]}],"title":"ANC +/- SEM after 2 cycles"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"dispersionType":"Standard Error","groups":[{"description":"Patients receive oral MS-275 on days 1, 8, 15, and 22. Patients also receive sargramostim (GM-CSF) subcutaneously once daily on days 1-42 in courses 3 and 5 and on days 1-35 in courses 1, 2, 4, and 6. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.\n\nentinostat: Given PO\n\nsargramostim: Given SC","id":"OG000","title":"Arm I"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline and after 2 cycles","title":"Clinical Activity Assessed by Change in Peripheral Blood Counts","type":"SECONDARY","unitOfMeasure":"cell/mm^3"}